Results 91 to 100 of about 530,731 (290)

Brain distribution of a bispecific antibody targeting Aβ

, 2022
Alzheimer’s disease (AD) is characterised by aberrant protein aggregation in the brain with subsequent synaptic loss, neuroinflammation, and brain atrophy that ultimately clinically manifests as cognitive impairment.
Tobias, Gustavsson
core   +2 more sources

Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1

We designed, produced, and purified a novel IgG1-like, bispecific antibody (bsAb) directed against B-cell maturation antigen (BCMA), expressed by multiple myeloma (MM) cells, and an immune checkpoint inhibitor (ICI), PDL1, expressed in the MM ...
Muriel Roth, Sylvie Choblet, Irene Cattaneo, Martine Duonor-Cerutti, Josée Golay, Marten Beeg, Marco Gobbi, Rut Valgardsdottir, Annamaria Massafra   +8 more
core   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

Improvement of therapeutic potential of the bispecific antibody.

, 2013
(A) Improving FVIII-mimetic activity of the bispecific antibody. Effect of hBS1 (circles), hBS106 (squares), and hBS910 (diamonds) on FX activation in the presence of FIXa, FX, and synthetic phospholipid is shown.
Miho Funaki (384395), Kunihiro Hattori (384401), Eriko Tanaka (384390), Takehisa Kitazawa (384392), Tatsuhiko Tachibana (384397), Yukiko Okuyama-Nishida (384387), Kenta Haraya (384396), Keiko Esaki (384399), Tetsuo Kojima (89773), Tomoyuki Igawa (384385), Kazutaka Yoshihashi (384393), Zenjiro Sampei (384384), Tetsuhiro Soeda (384386), Aya Harada (384394), Sachiyo Suzuki (384398), Atsushi Muto (384391), Tetsuya Wakabayashi (384389), Chifumi Moriyama (384388), Yoshiaki Nabuchi (384400)   +18 more
core   +1 more source

From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs

Clinical Pharmacology &Therapeutics, EarlyView.
New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and disease biology that are difficult
Karen Rowland Yeo, Piet H. van der Graaf
wiley   +1 more source

Metabolic Engineering of Glycofusion Bispecific Antibodies for α-Dystroglycanopathies

Background: α-dystroglycanopathies are congenital muscular dystrophies in which genetic mutations cause the decrease or absence of a unique and complex O-linked glycan called matriglycan. This hypoglycosylation of O-linked matriglycan on the α
Logan Riegel, Chris J. Corcoran, Teresse de Rham, Apurva Chaturvedi, Xiuling Li, Molica Abel, Laird Bloom, Guoying Grace Yan, Laura Lin, Yijie Gao, Aaron M. D’Antona, Xiaotian Zhong, Sean K.H. Lim, Edward R. LaVallie, Jing Zhou, Mahasweta Girgenrath, Liz Diblasio-Smith   +16 more
core   +1 more source

From Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Digital patients and in silico clinical trials offer new opportunities to advance pharmacological research, clinical development, and regulatory decision‐making by enabling the simulation of treatment effects prior to testing in patients. Among the most promising of these opportunities is the combined use of quantitative systems pharmacology (QSP) and ...
Thomas Klabunde, Ramon Hernandez, Piet H. van der Graaf, Tommaso Andreani   +3 more
wiley   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma

Nature Communications
Macrophages are critical effectors of antibody therapies for lymphoma, but the best targets to engage their function remain unknown. Here, we develop a ‘tactical surfaceome profiling’ strategy to define a comprehensive repertoire of surface antigens on B-
Carlota Pagès-Geli, Juliano Ribeiro, Thomas Wienclaw, Anna M. Meglan, Lauren Sloat, Matheus Silva, Jasmine Blandin, José Velarde, Kyle Vaccaro, Carolin Sebastiany, Patricia Fernández-Guzmán, Cynthia K. Hahn, Marta Crespo, Kipp Weiskopf   +13 more
doaj   +1 more source

Structure-Guided Stapling of Dimeric Conformations and Linker Engineering Enhance Thermostability and Fine-Tune Activity of Bispecific VHH Cytokine Agonists

Background: Bispecific antibodies have emerged as a promising class of therapeutics, enabling simultaneous targeting of two distinct antigens. Single-domain antibodies (sdAbs) comprising camelid variable heavy chains (VHHs) provide a compact and ...
Martin Oft, Priyanka Balasubrahmanyam, Andrew Morin, Ivan Cheng, Patrick Lupardus, Deepti Rokkam, Sandro Vivona, Raphael Trenker, Verenice Paredes, Rene de Waal Malefyt   +9 more
core   +1 more source